> YM Biosciences managed to halve its pre-tax loss for the first half by cutting expenses. Release
> French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's potential side effects. Report
> The Juvenile Diabetes Research Foundation is giving Plureon $500,000 over two year to research new treatments for type 1 diabetes. Report
> A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. Report
> When the American College of Cardiology sent out its annual meeting agenda, the controversial ENHANCE study wasn't listed as a highlighted presentation. Report
> Manhattan Pharmaceuticals has entered into a joint venture agreement with Nordic Biotech Advisors ApS (Nordic) to develop and commercialize Hedrin, the company's novel, non-insecticide treatment for head lice. Release
> Twenty-three people have died after being injected with colchicine, a gout drug that's FDA-approved only for oral use. Report
> A few hours of extreme drowsiness is not a bad trade-off for schizophrenia patients who have problems sticking to their medication. So said an FDA advisory committee yesterday in backing approval of Eli Lilly's new long-acting, injectable form of Zyprexa. Report
> Plummeting Avandia sales have taken a toll on GlaxoSmithKline's bottom line. Report
And Finally… Researchers can now use a transparent zebrafish to help them advance their understanding of disease. Release